PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms

February 16, 2005

(Philadelphia, PA) - A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.

Thoracic aortic aneurysms (TAAs) occur when a section of the aorta - the body's largest artery that carries blood out of the heart and into the organs of the body - weakens and bulges outward like a balloon in the section of the artery that runs down the chest. Each year, more than 20,000 patients in the United States are diagnosed with TAA. Aortic aneurysms - including thoracic and abdominal aortic aneurysms - remain the 13th major cause of death in this country, accounting for nearly 15,000 deaths annually.

"The STARZ-TX2 trial is groundbreaking and excellent news for patients diagnosed with descending thoracic aortic aneurysms," says Dr. Fairman. "Surgery can be life-threatening for many of these patients and a 'wait-and-see' approach is often not an option because patients are at an increased risk of an aortic rupture. A non-surgical approach to treating this life-threatening disease could benefit thousands of lives."

The clinical trial, called STARZ-TX2 (Study of Thoracic Aortic Aneurysm Repair with the Zenith® TX2™ Thoracic TAA Endovascular Graft), is open to patients diagnosed with a descending thoracic aortic aneurysm. STARZ-TX2 will compare the outcomes of patients treated with open surgery to patients treated with the Zenith TX2 Thoracic TAA Endovascular Graft, manufactured by Cook Incorporated.

Specifically, the trial will assess device performance, as well as patient survival and aneurysm rupture rates in the surgical and endovascular treatment groups, over a 12-month period.

The trial will enroll 275 patients at up to 35 medical institutions in the United States and Canada. Additional trial sites in Japan, Australia and Europe also will participate.

Currently, surgical repair is the standard of care for the treatment of TAAs. Surgical repair requires a surgeon to open the chest cavity, clamp off the aorta and sew a surgical graft in place to prevent an aneurysm from rupturing. Open surgical repairs carry high health risks for many older patients, who may also suffer from other significant medical conditions such as heart disease, lung disease, diabetes or hypertension.

The Zenith TX2 system requires an incision to insert the graft's hydrophilic, kink-resistant delivery system into the femoral artery in the leg. Once the system is guided into position through the patient's arteries under fluoroscopy, a one- or two-piece, fabric-covered, self-expanding stent graft is placed inside the weakened section of the thoracic aorta to relieve pressure on the aneurysm, helping to reduce the risk of rupture.

Endovascular treatment of aortic aneurysms has been a common practice for the past 10 years in the United States, Europe and Asia. During that time, significant improvements in treatment outcomes have been observed among patients treated with endovascular devices as compared with standard open surgery. Current endovascular treatments are marketed worldwide for the treatment of abdominal aortic aneurysms.

The major cause of thoracic aortic aneurysms is a hardening of the arteries, a condition in which fatty deposits adhere to the walls of the arteries, which become less elastic and weaker as a result. Major risk factors leading to a hardening of the arteries include smoking and high blood pressure as well as genetics. Other possible causes of TAA include trauma to the aorta and congenital diseases such as Marfan's syndrome.
-end-
Editor's Note You may also find this news release on-line at www.uphs.upenn.edu/news.

The University of Pennsylvania has an on-campus television studio with satellite uplink, live-shot capability for interviews with PENN Medicine experts.

About Penn Medicine

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system). Penn's School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System is comprised of three hospitals ( the Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital and Presbyterian Medical Center); a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home health care and hospice.

University of Pennsylvania School of Medicine

Related Aneurysm Articles from Brightsurf:

New abdominal aortic aneurysm genes identified, could help pinpoint those at risk
A study of US veterans identified 14 genes that may predict the risk of abdominal aortic aneurysm.

Temple researchers track new path to therapeutic prevention of abdominal aortic aneurysm
New research by scientists at the Lewis Katz School of Medicine at Temple University suggests that abdominal aortic aneurysm (AAA) can be prevented therapeutically.

Researchers find no benefit for treatment used to avoid surgery for abdominal aortic aneurysm
A new landmark study by researchers at the University of Maryland School of Medicine (UMSOM) found that patients with a vascular condition, called abdominal aortic aneurysm, received no benefits from taking a common antibiotic drug to reduce inflammation.

Genetic scoring can identify more men at risk for aortic aneurysm
A genetic risk score from a blood test identified more men age 50 and older who are at higher risk of an aortic aneurysm and could benefit from ultrasound screening.

New findings boost understanding of arterial aneurysm
Abdominal arterial (or aortic) aneurysm in older men is associated with levels of certain subtypes of white blood cells, a study from the University of Gothenburg, Sweden, shows.

Presence of blood clot associated with rapid aortic aneurysm growth
The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms is associated with more rapid, potentially dangerous growth in the aneurysm, according to a major new study.

Advances in the detection of the postoperative progress of abdominal aortic aneurysm
A study published in Frontiers in Bioengineering and Biotechnology by a team of researchers from BCN MedTech with the VICOMTech Foundation in San Sebastian, the BioDonostia Health Research Institute and Donostia University Hospital, offers a promising methodology for post-operative CTA time-series registration and subsequent aneurysm biomechanical strain analysis, which correlates with the patient's long-term prognosis.

Can aspirin decrease the rate of intracranial aneurysm growth?
Researchers investigated whether aspirin can aid in the prevention of intracranial aneurysm rupture by hindering aneurysm growth.

Researchers uncover new cause of abdominal aortic aneurysm
Researchers have discovered that a family of lipids (fats) contribute to the development of a serious aortic disease, by driving clotting in the blood vessel wall.

'Aneurysm Number' may help surgeons make treatment decisions
Aneurysms form as abnormal bulges over an artery, and, if ruptured, can lead to serious health complications or even death.

Read More: Aneurysm News and Aneurysm Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.